CN117562912A - Application of radish glycoside in preparation of medicine for promoting postoperative gastrointestinal function recovery - Google Patents
Application of radish glycoside in preparation of medicine for promoting postoperative gastrointestinal function recovery Download PDFInfo
- Publication number
- CN117562912A CN117562912A CN202311529632.2A CN202311529632A CN117562912A CN 117562912 A CN117562912 A CN 117562912A CN 202311529632 A CN202311529632 A CN 202311529632A CN 117562912 A CN117562912 A CN 117562912A
- Authority
- CN
- China
- Prior art keywords
- radish
- glycoside
- pharmaceutically acceptable
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000220259 Raphanus Species 0.000 title claims abstract description 69
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 title claims abstract description 69
- 229930182470 glycoside Natural products 0.000 title claims abstract description 58
- 150000002338 glycosides Chemical class 0.000 title claims abstract description 58
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 27
- 238000011084 recovery Methods 0.000 title claims abstract description 20
- 230000001737 promoting effect Effects 0.000 title claims abstract description 16
- 230000007661 gastrointestinal function Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims description 13
- 230000002496 gastric effect Effects 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 241001673966 Magnolia officinalis Species 0.000 claims description 13
- UPNUIXSCZBYVBB-JVFUWBCBSA-N alvimopan Chemical compound C([C@@H](CN1C[C@@H]([C@](CC1)(C)C=1C=C(O)C=CC=1)C)C(=O)NCC(O)=O)C1=CC=CC=C1 UPNUIXSCZBYVBB-JVFUWBCBSA-N 0.000 claims description 13
- 229960004516 alvimopan Drugs 0.000 claims description 8
- 230000005176 gastrointestinal motility Effects 0.000 claims description 8
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims description 6
- -1 pra Lu Kaluo pride Chemical compound 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims description 3
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 claims description 3
- 229960003526 acipimox Drugs 0.000 claims description 3
- 229960002921 methylnaltrexone Drugs 0.000 claims description 3
- 235000014347 soups Nutrition 0.000 claims description 3
- 244000223014 Syzygium aromaticum Species 0.000 claims description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000003399 chemotactic effect Effects 0.000 claims 1
- 239000013583 drug formulation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 230000013872 defecation Effects 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 206010033799 Paralysis Diseases 0.000 abstract description 6
- 210000002784 stomach Anatomy 0.000 abstract description 6
- 206010054048 Postoperative ileus Diseases 0.000 abstract description 5
- 208000004998 Abdominal Pain Diseases 0.000 abstract description 4
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 abstract description 4
- 206010066962 Procedural nausea Diseases 0.000 abstract description 4
- 206010047700 Vomiting Diseases 0.000 abstract description 4
- 230000008673 vomiting Effects 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract description 3
- 210000000813 small intestine Anatomy 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000010171 animal model Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 5
- 241000283977 Oryctolagus Species 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001187 pylorus Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000218378 Magnolia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 230000004212 intestinal function recovery Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009295 sperm incapacitation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 description 1
- 108010048829 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Proteins 0.000 description 1
- 102000009453 Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003886 intestinal anastomosis Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical class N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of radish glycoside in preparing a medicament for promoting postoperative gastrointestinal function recovery, and belongs to the technical field of postoperative gastrointestinal function recovery. Compared with the prior art, the radish glycoside has obvious treatment effect on postoperative gastrointestinal paralysis (postoperative ileus, POI), can enable the stomach and intestine of a patient to recover normal functions in advance in a targeted manner, and avoids symptoms such as postoperative nausea, vomiting, abdominal pain, stopping exhaustion, defecation and the like.
Description
Technical Field
The invention belongs to the technical field of postoperative gastrointestinal recovery, relates to application of radish glycoside in preparing a medicament for promoting postoperative gastrointestinal function recovery, and in particular relates to application of radish glycoside, pharmaceutically acceptable salt or pharmaceutical composition thereof in preparing a medicament for promoting postoperative gastrointestinal function recovery.
Background
The postoperative enteroparalysis (postoperative ileus, POI), also called postoperative gastrointestinal dysfunction (postoperative gastrointestinal dysfunction, POGD), is a clinical phenomenon that gastrointestinal motility function is temporarily inhibited after surgery due to non-mechanical factors to cause incapacitation of oral intake, is defined as prolonged gastrointestinal function recovery time after surgery due to non-mechanical factors to cause incapacitation of oral intake of a patient, and is characterized by impaired gastrointestinal peristalsis function, and clinically manifested as postoperative nausea, vomiting, abdominal pain, and cessation of evacuation, defecation, and the like. The pathogenesis of the disease is related to a plurality of factors such as surgical trauma, narcotic drugs, sympathetic nervous system hyperfunction, intestinal inflammatory response and the like. POI is divided into early neurogenic stage and later inflammatory stage, the inflammatory stage has great influence on organism and clinical prognosis, and can avoid later inflammatory stage and relieve or avoid related symptoms by treatment in advance.
The radish glycoside is an active ingredient of the traditional Chinese medicinal material stir-fried radish seeds, has the effect of promoting gastrointestinal motility, has researches and shows that the completion of the promotion effect of the radish glycoside on gastrointestinal motility is mainly dependent on the activation effect of HCN1 channels on colon mucosa ICC, and the morphological change effect of the radish glycoside on ICC is similar to the effect of traditional gastric motility medicine gastric reset (Xu Chun, research on the distribution characteristics of the gastrointestinal tracts and the effect of the HCN1 on the radish glycoside, university of army medical science thesis, 2013, 5 months), and has no characteristic related report and application for relieving and treating postoperative enteroparalysis (postoperative ileus, POI) at present.
Disclosure of Invention
The invention aims to provide an application of radish glycoside in preparing a medicament for promoting postoperative gastrointestinal function recovery; in particular to the application of the radish glycoside, the pharmaceutically acceptable salt or the pharmaceutical composition thereof in preparing medicines for treating postoperative gastrointestinal dysfunction. Experiments prove that the medicine effect of the radish glycoside of the invention on the postoperative enteroparalysis animal model is equivalent to or even better than that of the drug Alvimopan approved by the FDA in the United states.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
in a first aspect, the present invention provides the use of a radish glycoside, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the preparation of a medicament for promoting the recovery of gastrointestinal function after surgery.
In a second aspect, the present invention provides the use of a radish glycoside, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the preparation of a medicament for the treatment of post-operative gastrointestinal dysfunction.
The radish glycoside is prepared from radish seeds by stir-frying and then extracting or artificially synthesizing. The radish glycoside can also be extracted from other cruciferous plants. CAS number: 28463-24-3 has the following structure.
The invention relates to a pharmaceutical composition, which comprises radish glycoside or pharmaceutically acceptable salt thereof and pharmaceutically acceptable auxiliary materials.
In some embodiments, the pharmaceutical composition further comprises an additional gastrointestinal motility-promoting drug as a second active ingredient that works in combination with the radish glycoside or a pharmaceutically acceptable salt thereof to promote postoperative gastrointestinal function recovery or treat postoperative gastrointestinal dysfunction.
The other medicines for promoting gastrointestinal motility are chemical medicines, traditional Chinese medicines or Chinese patent medicine preparations. Wherein the chemical is selected from alvimopan, metoclopramide, methylnaltrexone, pra Lu Kaluo pride, acipimox, epalresta Mo Leilin and Wu Limo forest; the Chinese medicine is selected from magnolia officinalis and clove; the Chinese patent medicine preparation is selected from magnolia bark air-exhausting mixture and four-grinding soup.
The medicine composition is formed by directly mixing the radish glycoside or pharmaceutically acceptable salt thereof with other medicines for promoting gastrointestinal peristalsis or respectively and independently packaging the radish glycoside or the pharmaceutically acceptable salt thereof.
In a third aspect, the invention provides a pharmaceutical composition or combination comprising radish glycoside or a pharmaceutically acceptable salt thereof and other gastrointestinal motility promoting drugs.
The beneficial effects of the invention are as follows:
(1) Experiments prove that the radish glycoside does not need preoperative administration, has obvious curative effect on postoperative enteroparalysis caused by open intestinal tract exploration of animals, and can shorten the time required by restoring normal functions of gastrointestinal tracts.
(2) Experiments prove that the effect of the radish glycoside on the appearance time of borborygmus, the first defecation time and the small intestine pushing rate is superior to that of the magnolia bark exhaust mixture and the alvimopan, and the radish glycoside has better quality effect.
(3) Compared with the prior art, the radish glycoside has obvious treatment effect on postoperative gastrointestinal paralysis (postoperative ileus, POI), can enable the stomach and intestine of a patient to recover normal functions in advance in a targeted manner, and avoids symptoms such as postoperative nausea, vomiting, abdominal pain, stopping exhaustion, defecation and the like.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention.
Before the embodiments of the invention are explained in further detail, it is to be understood that the invention is not limited in its scope to the particular embodiments described below; it is also to be understood that the terminology used in the examples of the invention is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The invention does not limit the sources of the adopted raw materials, and if no special description exists, the adopted raw materials are all common commercial products in the technical field.
The term "pharmaceutically acceptable salts" as used herein includes salts derived from suitable bases such as alkali metals or alkaline earth metals (e.g., na + 、Li + 、K + 、Ca 2+ And Mg (magnesium) 2 ) + And ammonium; physiologically acceptable salts of nitrogen atoms or amino groups include: (a) Acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like; (b) Salts with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, isethionic acid, lactobionic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, malonic acid, sulfosalicylic acid, glycolic acid, 2-hydroxy-3-naphthoate, pamoate, salicylic acid, stearic acid, phthalic acid, mandelic acid, lactic acid, ethanesulfonic acid, lysine, arginine, glutamic acid, glycine, serine, threonine, alanine, isoleucine, leucine and the like; and (c) salts with elemental anions such as chlorine, bromine, and iodine; physiologically acceptable salts of hydroxy compounds include anions of said radish glycosides with, for example, na + Combinations of suitable cations.
For therapeutic use, the salts of the active ingredient of the present radish glycosides are physiologically acceptable, i.e. they are salts derived from physiologically acceptable acids or bases. However, salts of acids or bases that are not physiologically acceptable may also be used, for example, to prepare or purify physiologically acceptable compounds. All salts, whether or not derived from physiologically acceptable acids or bases, are within the scope of the invention.
The "pharmaceutical composition" described herein comprises the radish glycoside or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant, and in particular embodiments, the radish glycoside or a pharmaceutically acceptable salt thereof described herein is provided in an effective amount (e.g., a therapeutically effective amount) in a pharmaceutical composition.
The "pharmaceutically acceptable auxiliary materials" in the present invention include inert diluents, dispersants and/or granulating agents, surfactants and/or emulsifying agents, disintegrants, binders, preservatives, buffers, lubricants and/or oils. Excipients (e.g., cocoa butter and suppository waxes), colorants, coatings, sweeteners, flavoring agents and fragrances may also be present in the pharmaceutical composition.
The "pharmaceutical composition" described in the present invention may be prepared by any method known in pharmacy. Generally, these methods of preparation comprise associating the radish glycoside or a pharmaceutically acceptable salt thereof (i.e., the first active ingredient) with a carrier or excipient and/or one or more other auxiliary ingredients, and then shaping and/or packaging the product into the desired single-dose or multi-dose unit, if needed and/or desired.
The pharmaceutical composition of the present invention can be prepared according to a known method, for example, the method set forth in the general rules for the preparation of japanese pharmacopoeia (Japanese Pharmacopoeia) 16 th edition, united states pharmacopoeia (United States Pharmacopoeia) and european pharmacopoeia (European Pharmacopoeia) 9 th edition. Depending on the dosage form, the pharmaceutical composition of the present invention may be suitably administered to a patient.
The first active ingredient, pharmaceutically acceptable excipients in the "pharmaceutical compositions" described herein will vary according to the nature, size and/or condition of the subject being treated and further according to the route of administration of the composition. The pharmaceutical composition may comprise between 0.1% and 100% (w/w) of the first active ingredient.
The "pharmaceutical composition" according to the invention may optionally also comprise other therapeutic ingredients for compatible use, in particular those additional therapeutic ingredients as disclosed herein, such as "other gastrointestinal motility promoting drugs" (i.e. second active ingredient), wherein the pharmaceutical agents include alvimopan, pepsin and the drugs under investigation methylnaltrexone, pra Lu Kaluo prine, acipimox, epap Mo Leilin, wu Limo, etc.; the Chinese medicinal materials comprise cortex Magnolia officinalis, flos Caryophylli, etc.; chinese patent medicine preparations such as magnolia bark mixture for exhausting qi, four-grinding soup and the like; meanwhile, the medicine composition can be matched with other treatment means, such as acupuncture, chewing gum after operation, and the like.
The term "treating" as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progression of, or preventing a disorder or condition for which the term applies or one or more symptoms of such disorder or condition. The term "treatment" as used herein refers to a therapeutic action, as defined immediately above.
As used herein, an "effective amount" refers to an amount sufficient to elicit the desired biological response. The effective amount of the active ingredients of the present invention may vary depending on factors such as: the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, the effective amount is a therapeutically effective amount. An effective amount is the amount of the first active ingredient described herein in a single dose. In certain embodiments, the effective amount is the combined amount of the active ingredients set forth in the present invention in multiple doses.
A "therapeutically effective amount" as used herein is an amount sufficient to provide a therapeutic benefit in the treatment of a disorder or to delay or minimize one or more symptoms associated with the disorder. A therapeutically effective amount of a radish glycoside or a pharmaceutically acceptable salt thereof means an amount of the therapeutic agent alone or in combination with other therapies to provide a therapeutic benefit in the treatment of a disorder. The term "therapeutically effective amount" may encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or etiology of a disorder, and/or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient to treat any of the diseases or conditions set forth.
1. Description of animal model selection
The postoperative gastrointestinal paralysis, the disorder of the conventional functions and the like can be caused by factors such as minor inflammation caused by preoperative anesthesia, peritoneal irritation, examination and the like after the conventional abdominal operation. Delayed recovery of gastrointestinal function after surgery may cause other complications such as intestinal adhesion, ileus, etc. The gastrointestinal function can be recovered as soon as possible, the generation of related complications can be avoided, and the solid food can be tolerated in advance. The related drug effect study is carried out by using an animal model, so that gastrointestinal paralysis is caused for simulating an open-abdomen exploration operation. Or simulate an intestinal resection anastomosis procedure. The core drug effect data of the two animal models are normal rhythmic peristaltic recovery time of gastrointestinal tracts, and the detection standards are intestinal propulsion and bowel movement and defecation occurrence time.
2. Animal efficacy model for postoperative enteroparalysis of rats
1. Moulding
After 24 hours of fasted, water is not forbidden, the rats are anesthetized and prepared by injecting 1% sodium pentobarbital into the abdominal cavity, and the abdominal incision is conventionally disinfected by iodine and then laid with sterile gauze. And (3) cutting a vertical incision along the mid-line of the abdomen, gently taking out the intestinal tract of the rat, placing the rat on sterile gauze, repeatedly wiping the wet cotton swab soaked by sodium chloride solution for 5min from the distal end of the duodenum to the cecum, and preferably achieving moderate congestion and edema of the small intestine. After the intestinal operation is finished, the small intestine is gently put back into the abdominal cavity, the abdominal muscle layer and the cortex wound are respectively sutured, and the wound periphery is disinfected to prevent infection.
Blank group, no water control after 24 hours of fasting, anesthesia, standing for 5min after rat has opened abdomen, taking out small intestine without wiping, and other operations are the same as the model group.
2. Test group and administration
Animal origin of SD rat used: shanghai Laike laboratory animal Limited; license number: SCXK (Shanghai)
2022-0004; pass number: 20220004032973.
rats were randomly divided into eight groups of 12 animals each, each group consisting of a blank group, a model group, a radish seed extract group, two medium and high doses of radish glycoside, and three positive drug groups. The administration is performed by gastric lavage 3, 6 and 12 hours after operation, and the dosage of each gastric lavage is equal. The sum of the three doses is as follows: the radish seed extract group is 264mg/kg; the dosage group of the radish glycoside is 50mg/kg; the high dosage group of the radish glycoside is 100mg/kg; 21ml/kg of magnolia bark exhaust mixture group; alvimopan group 10.5mg/kg, and Weifuan group 50mg/kg. The specific dose is measured according to animal body weight.
The preparation method of the radish seed extract in the radish seed extract group comprises the following steps: crushing Raphani semen into powder, sieving with 80 mesh sieve, extracting Raphani semen with water for 2 hr, filtering, concentrating the filtrate, drying at 70deg.C for 18 hr, and granulating.
3. Detection of
Filling the stomach with ink: the small intestine thrust rate was calculated using ink, and each group of rats was subjected to gastric lavage with an ink using a gastric lavage needle at each observation time point. Small intestine ink push rate, 30min after stomach irrigation, neck removal and sacrifice. After the abdominal cavity is opened, the mesentery is separated, the intestinal canal with the upper end from the pylorus and the lower end to the ileocecum is cut, and the intestinal canal is placed on a tray to draw the small intestine into a straight line. The length of the intestinal canal was measured as "total length of small intestine", and from pylorus to ink front as "ink push length". Ink push rate. The calculation formula is that the advancing length (cm) of the ink is equal to the total length (cm) of the small intestine multiplied by 100 percent.
4. Results
As shown in table 1, after 3, 6, 12 hours of gastric lavage administration, the ink thrust rates of rats 72h and 120h of the model group, the blank group, the radish glycoside medium dose group, the radish glycoside high dose group, the magnolia exhaust mixture group and the alvimopan group all have extremely significant differences (P < 0.01), and the blank group, the radish glycoside medium dose group, the radish glycoside high dose group, the magnolia exhaust mixture group and the alvimopan group have no significant differences, which indicates that: the radish glycoside can promote the recovery of intestinal functions and has the same effect as the magnolia bark exhaust mixture and the alvimopan.
After 3, 6 and 12 hours of gastric lavage administration, compared with a model group, the radish seed extract group and the gastric recovery group have no significant differences (P > 0.05) in the ink propelling rates of rats 24h, 72h and 120h, and show that the radish seed extract and the gastric recovery group have no effect on intestinal function recovery.
Meanwhile, compared with the radish seed extract group, the radish glycoside medium dose group (72 h and 120 h) and the radish glycoside high dose group rats (24 h, 72h and 120 h) have extremely significant differences (P < 0.01), which indicates that: the radish glycoside has better effect in promoting intestinal function recovery than radish seed extract.
In conclusion, the time required by gastrointestinal tract normal function recovery can be shortened by the administration of the radish glycoside through postoperative gastric lavage, the recovery of intestinal functions of an animal model is quickened, and the oral administration method has obvious curative effects on postoperative enteroparalysis caused by open intestinal tract exploration of animals.
TABLE 1
Note that P <0.01 compared to model group; compared with the radish seed extract group, #P <0.01.
3. Animal efficacy model for gastrointestinal paralysis after rabbit operation
1. Moulding
New Zealand rabbits were fasted without water inhibition for 24 hours, were anesthetized by intravenous injection of sodium pentobarbital, were conventionally sterilized in the abdomen, and were closed after performing anastomosis by taking out and cutting 5cm from the colon of the ileocecum, and performing intestinal anastomosis. The blank group was subjected to a sham operation, i.e., suturing after opening the abdomen. Of 24 animals in each group, 12 were observed for borborygmus and first bowel movement time, and 12 were examined for small intestine thrust.
2. Test group and administration
New Zealand rabbits, offered by the medical laboratory animal center in Guangdong province, have a weight range of 2.6-3.0kg. Production license number: SCXK (Yue) No. 2022-0002, quality eligibility number: 20220004050397. and (3) feed sources: is provided by the Guangdong provincial animal center for medical experiments.
56 New Zealand rabbits are divided into a blank group, a model group, a low-dose group, a medium-dose group and a high-dose group of the radish glycoside and two groups of the positive medicine according to the weight. The administration is performed by gastric lavage 3, 6 and 12 hours after operation, and the dosage of each gastric lavage is equal. The sum of the three doses is as follows: 66mg/kg of radish glycoside low dose group; the dosage group of the radish glycoside is 132mg/kg; the high dosage group of the radish glycoside is 264mg/kg; 21ml/kg of magnolia bark exhaust mixture group; the positive medicine alvimopan is 10.5mg/kg. The specific dose is measured according to animal body weight.
3. Detection of
Postoperative borborygmus recovery condition and first defecation time: after completion of the operation for 6 hours, the bowel sounds were recorded 1 time every 1 hour, and the first bowel movement time was determined from the image recording.
Calculating the small intestine propulsion rate: animals are fasted without water control, 5% of active carbon powder suspension is given after the last administration for 1h, 20 mL/animal is sacrificed after 20min after stomach irrigation, small intestines (pylorus to ileocecum) are taken out, the animal is laid on a glass plate without traction, the whole length of the animal and the distance from the front edge of the carbon powder to the pylorus are measured, and the small intestine propulsion rate is calculated. The calculation formula is the same as that of the animal model 1.
4. Results
As can be seen from table 2, in rabbit surgery, there was a very significant difference (P < 0.01) in total borborygmus appearance time, first bowel movement time and small intestine push rate of new zealand rabbits in the blank group, the low-dose group of raphanin, the medium-dose group of raphanin, and the high-dose group of raphanin, compared to the modules, and there was no significant difference between the groups, indicating that: the radish glycoside can shorten the appearance time of total borborygmus after operation and the first defecation time, and improve the small intestine push rate.
Meanwhile, the total borygmus appearance time and the first defecation time of the radish glycoside high-dose group of the post-operation New Zealand rabbits are shorter than those of the magnolia officinalis exhaust mixture group and the alvimopan group, and the small intestine pushing rate is superior to those of the magnolia officinalis exhaust mixture group and the alvimopan group, so that the effect of the radish glycoside on the aspects of borygmus appearance time, the first defecation time and the small intestine pushing rate is superior to those of the magnolia officinalis exhaust mixture and the alvimopan, and the radish glycoside has better quality effect.
TABLE 2
Note that P <0.01 compared to model group.
In conclusion, the radish glycoside has obvious treatment effect on postoperative gastrointestinal paralysis (postoperative ileus, POI), can enable the intestines and stomach of a patient to recover normal functions in advance in a targeted manner, and avoids symptoms such as postoperative nausea, vomiting, abdominal pain, stopping exhaustion, defecation and the like.
The invention has been further described above in connection with specific embodiments, which are exemplary only and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
Claims (10)
1. Use of a radish glycoside, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the preparation of a medicament for promoting the recovery of gastrointestinal function after surgery.
2. Use of a radish glycoside, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the preparation of a medicament for the treatment of post-operative gastrointestinal dysfunction.
3. The use according to claim 1 or 2, wherein the pharmaceutical composition comprises radish glycoside or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant.
4. The use according to claim 1 or 2, wherein the pharmaceutical composition comprises a further gastrointestinal motility promoting drug.
5. The use according to claim 4, wherein the other gastrointestinal motility-promoting drug is a chemo-, chinese-or chinese-patent drug formulation.
6. The use according to claim 5, wherein the chemotactic agent is selected from the group consisting of alvimopan, metoclopramide, methylnaltrexone, pra Lu Kaluo pride, acipimox, epap Mo Leilin and Wu Limo.
7. The use according to claim 5, wherein the traditional Chinese medicine is selected from magnolia officinalis and clove.
8. The use according to claim 5, wherein the chinese patent medicine preparation is selected from the group consisting of magnolia bark exhaustion mix and tetraground soup.
9. The use according to claim 4, wherein the pharmaceutical composition is a combination of the radish glycoside or a pharmaceutically acceptable salt thereof and other gastrointestinal motility promoting drugs, either directly mixed together or packaged separately.
10. A pharmaceutical composition or combination comprising radish glycoside or a pharmaceutically acceptable salt thereof and other gastrointestinal motility-promoting agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311529632.2A CN117562912A (en) | 2023-11-16 | 2023-11-16 | Application of radish glycoside in preparation of medicine for promoting postoperative gastrointestinal function recovery |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311529632.2A CN117562912A (en) | 2023-11-16 | 2023-11-16 | Application of radish glycoside in preparation of medicine for promoting postoperative gastrointestinal function recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117562912A true CN117562912A (en) | 2024-02-20 |
Family
ID=89863772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311529632.2A Pending CN117562912A (en) | 2023-11-16 | 2023-11-16 | Application of radish glycoside in preparation of medicine for promoting postoperative gastrointestinal function recovery |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117562912A (en) |
-
2023
- 2023-11-16 CN CN202311529632.2A patent/CN117562912A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1684770E (en) | Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer | |
| CN106361993A (en) | Medicinal composition for preventing and treating gastric mucosal lesion and preparation method of medicinal composition | |
| CN107137417B (en) | Pharmaceutical composition for treating cachexia and application thereof | |
| CN111346158A (en) | Application of traditional Chinese medicine composition in treating gastrointestinal dysfunction | |
| CN101279022A (en) | Preparation of Simotang enema and suppositorium | |
| CN117562912A (en) | Application of radish glycoside in preparation of medicine for promoting postoperative gastrointestinal function recovery | |
| CN102106999B (en) | A kind of compound Chinese medicinal preparation for the treatment of dysphagia after apoplexy and preparation method thereof | |
| CN110652510B (en) | Application of Zhongwuning in preparing medicine for preventing and treating renal fibrosis | |
| US20090297643A1 (en) | Botanical composition and its uses | |
| CN102526013A (en) | Medicament composition and application thereof | |
| US4918193A (en) | Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion | |
| CN101007014B (en) | A compound puerarin preparation | |
| CN106511394B (en) | Application of aspongopus fatty oil extract | |
| CN110755486A (en) | Maxingshigan decoction flavored traditional Chinese medicine formula for treating nasosinusitis | |
| CN110721310B (en) | Application of pharmaceutical composition in preparation of medicine for treating acute hemorrhagic brain injury | |
| CN113577090B (en) | Application of arctiin in preparation of prostatic hyperplasia medicine | |
| CN110652511B (en) | Application of Zhongwuning in preparation of medicine for preventing and treating renal failure | |
| CN115531381B (en) | Application of immunomodulatory compound in preparation of medicine for treating pancreatitis | |
| CN103142909B (en) | Orally traditional Chinese medicine composition for treating lung cancers | |
| WO2023232090A1 (en) | Compound for treating hemorrhagic diseases and composition thereof | |
| JP2002265354A (en) | Anti-helicobacter pylori agent composition | |
| CN112358477A (en) | Medicine for treating cholecystitis and preparation method thereof | |
| CN112438982A (en) | Pharmaceutical composition and application thereof | |
| CN117427061A (en) | Application of luteolin and its derivatives in preparing antitumor drugs | |
| CN111759925A (en) | A Chinese medicinal composition for treating adnexitis and pelvic inflammatory disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |